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A B S T R A C T 
Introduction: Studies of Caucasian populations 
have shown that beta-blockers may exacerbate 
weight gain, a risk factor for many chronic diseases. 
Still, beta-blockers are the most prescribed 
antihypertensives in the Chinese population in Hong 
Kong. We aimed to explore the association between 
beta-blocker use, hypertension, and weight status of 
this population.
Methods: A post-hoc analysis regarding body 
mass index (BMI) and the use of beta-blockers 
was performed based on the medication profile of 
community-dwelling older adults. Participants’ 
BMI, hypertension diagnosis, name, dose, frequency, 
route of administration of beta-blockers, and other 
drugs that may alter body weight were recorded.
Results: Of 1053 Chinese individuals aged ≥65 
years (mean age 76.9±7.2 years, 80% female) from 
32 elderly centres in Hong Kong, 18% (185/1053) of 
them consumed beta-blockers. That group also had 
a significantly larger proportion of obese individuals 
(45.9% vs 32.1%, P=0.002). After adjusting for other 
weight-altering drugs, beta-blockers remained a 
significant predictor of overweight and obesity 
(P=0.001). As the hypertensive population had 
significantly higher BMI than the normotensive 
population (24.3±3.6 vs 22.9±3.5, P<0.001), a sub-
analysis on those with hypertension diagnosis 
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Introduction
Hypertension is highly prevalent and a key risk 
factor for cardiovascular disease.1 Less well 
recognised by patients and health professionals 
alike is that some of the pharmacotherapies used 
to treat hypertension may adversely impact other 
cardiovascular risk factors by causing weight gain. 
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More specifically, the weight gain effects of beta-
adrenergic antagonists (beta-blockers) have been 
highlighted by many studies of Caucasian patients.2-5 
Many guidelines no longer list beta-blockers as 
first-line antihypertensives.6-8 However, the 2018 
hypertension guidelines published by the European 
Society of Cardiology and the European Society of 
ORIGINAL ARTICLE
confirmed that only the hypertensive population 
taking atenolol had a significantly larger population 
of obese individuals (BMI ≥25) compared with those 
who took metoprolol (58.9% vs 38.5%, P=0.03) and 
those who did not take any beta-blockers (58.9% vs 
38.4%, P=0.007).
Conclusions: Our findings taken together with other 
guideline reservations cast doubt on whether beta-
blockers, particularly atenolol, should be the major 
drug prescribed to older adults with hypertension.
This article was 
published on 22 Jan 
2020 at www.hkmj.org.
New knowledge added by this study
• Beta-blocker consumption is associated with obesity in Chinese older adults.
• Hypertensive population taking atenolol had the largest portion of obesity.
• Strong and unique association of obesity and atenolol usage.
Implications for clinical practice or policy
• Healthcare professionals should be more vigilant concerning initiation of therapy for hypertension and ongoing 
surveillance of weight, such as carefully assessing baseline characteristics (including both body mass index 
and blood pressure status) before prescribing a beta-blocker, and regular monitoring of both parameters in 
hypertension treatment, particularly for patients with obesity and those who have not yet become obese if beta-
blockers are prescribed.
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Hypertension,9 the joint statement published in 
2012 by the European Society of Hypertension and 
the European Association for the Study of Obesity,10 
and a position paper of The Obesity Society and the 
American Society of Hypertension11 still advocate 
the use of beta-blockers in patients with both 
hypertension and obesity because beta-blockade 
is more effective in lowering blood pressure (BP) 
in patients with obesity than in patients who are 
thinner.12 In Hong Kong, two recent large database 
studies found that beta-blockers are still the most 
commonly prescribed antihypertensives, although 
they are used relatively less in younger patients 
aged <55 years.13,14 Furthermore, only 4% of Hong 
Kong patients have their antihypertensive treatment 
upgraded by changing from beta-blockers to first-
line agents.15
 The generally increasing prevalence of 
obesity among older adults is an important factor 
in drug-induced weight gain.16 Studies have shown 
that obesity in older people is associated with 
functional impairment and co-morbidity, including 
hypertension, type 2 diabetes, coronary heart 
disease, heart failure, and dementia.17-19 These 
chronic conditions, for which being overweight 
is a risk factor, are also worryingly increasing in 
prevalence.20-22 This renders weight management in 
older persons an important health issue.
 To date, there has been a lack of research to 
confirm the weight gain effects of beta-blockers in 
non-Caucasian populations, and this is particularly 
germane because so many older Chinese patients with 
hypertension are still receiving beta-blocker therapy.
 The objective of this study was to explore the 
association between beta-blocker use, hypertension, 
and overweight/obesity in a cohort of older Chinese 
people. The specific objectives were to: (1) identify 
the proportion of patients prescribed beta-blockers; 
(2) compare the body mass index (BMI) of beta-
blocker users with non-users; and (3) compare the 
effects of different beta-blockers on BMI.
Methods
Study design
A post-hoc analysis was undertaken using an 
existing dataset comprising the medication profiles 
of a cohort of community-dwelling older adults 
in Hong Kong. The data were originally collected 
(July to August in 2016) for a primary study seeking 
to explore the relationship between diet and the 
prevalence of atrial fibrillation.23 The study was 
approved by the Survey and Behavioural Research 
Ethics Committee of The Chinese University of 
Hong Kong and was conducted in accordance with 
the Declaration of Helsinki. Written informed 
consent was obtained from all study participants. 
Confidentiality agreement forms were signed by all 
data collectors. STROBE reporting guidelines were 
implemented in this manuscript.
Study population
The original study cohort comprised 1665 people 
attending one of 32 neighbourhood elderly 
recreational community centres in Hong Kong. The 
inclusion criteria included those who were Hong 
Kong Chinese residents, aged ≥65 years, living in 
the community, and able to speak and understand 
Cantonese. The exclusion criteria included those 
with terminal health conditions and/or significant 
cognitive impairment that would preclude 
participation because of communication barriers 
(eg, severe mental illness, dementia).
Data collection
All primary study data were collected during a 
summer community outreach programme—a 
territory-wide medical outreach service in Hong 
Kong provided by volunteer students from the 
Faculty of Medicine, The Chinese University of Hong 
Kong. The data were originally collected via face-to-
face interviews with the participants in Cantonese 
and recorded on paper-based questionnaires by 
trained volunteer students.
 At each outreach visit, participants’ body 
weight, height, and BP were measured, BMI 
calculated, medication profile extracted, and 
demographic data recorded. Calculated BMIs were 
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compared with the Asian BMI classification set 
by the World Health Organization, in which BMI 
≥23 and ≥25 are considered as overweight and 
obese, respectively.24 A self-reported diagnosis of 
hypertension and diabetes was recorded and verified 
against the patient’s current medication profile. 
The self-reported diagnosis of hypertension was 
the only evidence to determine whether the patient 
had hypertension or not. As part of the logistics 
and service provided by our outreach, BP was also 
measured using an Omron HEM-7011TM electronic 
blood pressure monitor (Omron Healthcare, Kyoto 
Japan), which has an “A/A” performance classification 
under British Hypertension Society criteria (ie, 
indicating that at least 80% and 95% of readings 
are within an absolute difference of 5 to 10 mm Hg 
from each other, respectively25). The readings were 
compared against 2017 American Heart Association 
guidelines,6 but such readings were not used to 
diagnose hypertension. To ensure accuracy, for each 
patient, the BP measurements were repeated after 
10 minutes of rest when the first reading was found 
to be elevated (ie, BP >120/80 mm Hg). When a 
beta-blocker had been prescribed, the name, dose, 
frequency, and route of administration of the agent 
were additionally recorded. The consumption of 
other drugs known to alter body weight was also 
recorded and listed in Table 1.







Male sex 207 (20%) 38 (21%) 169 (19%)
Age (years) 76.9 ± 7.2 77.6 ± 7.0 76.7 ± 7.2
65-74 415 (39%) 61 (33%) 354 (41%)
75-84 470 (45%) 92 (50%) 378 (44%)
85-100 168 (16%) 32 (17%) 136 (15%)
BMI (kg/m2) 23.7 ± 3.6 24.6 ± 3.7 23.6 ± 3.6
BMI category (WHO Asian classifications)
Underweight (<18.5) 61 (6%) 6 (3%) 55 (6%)
Normal (18.5 to <23) 422 (40%) 59 (32%) 363 (42%)
Overweight (23 to <25) 206 (20%) 35 (19%) 171 (20%)
Obese (≥25) 364 (35%) 85 (46%) 279 (32%)
Diagnosis of hypertension (self-reported) 626 (59%) 175 (95%) 451 (52%)
Diagnosis of diabetes (self-reported) 192 (18%) 48 (26%) 144 (17%)
Blood pressure category (2017 AHA/ACC Guideline)
Normal (SBP <120 mm Hg and DBP <80 mm Hg) 118 (11%) 20 (11%) 98 (11%)
Prehypertension (SBP=120-129 mm Hg and DBP <80 mm Hg) 131 (12%) 12 (7%) 119 (14%)
Hypertension stage 1 (SBP=130-139 mm Hg or DBP=80-89 
mm Hg)
226 (22%) 32 (17%) 194 (22%)
Hypertension stage 2 (SBP ≥140 mm Hg or DBP ≥90 mm Hg) 578 (55%) 121 (65%) 457 (53%)
Drug/drug classes associated with weight gain
Insulin 15 (1%) 4 (2%) 11 (1%)
Sulfonylureas 91 (9%) 26 (14%) 65 (6%)
Corticosteroids 9 (0.9%) 3 (2%) 6 (0.7%)
Antipsychotics 4 (0.4%) 2 (1%) 2 (0.2%)
Antidepressants 19 (2%) 7 (4%) 12 (1%)
Anticonvulsants 9 (0.9%) 1 (0.5%) 8 (0.9%)
Anti-parkinsons 1 (0.1%) 0 1 (0.1%)
Drug/drug classes associated with weight loss
Metformin 168 (16%) 43 (23%) 125 (14%)
Loop diuretics 34 (3%) 9 (5%) 25 (3%)
Weight-loss antidepressant 7 (0.7%) 3 (2%) 4 (0.5%)
Abbreviations: AHA/ACC = American Heart Association/American College of Cardiology; BMI = body mass index; DBP = diastolic 
blood pressure; SBP = systolic blood pressure; WHO = World Health Organization
* Data are shown as No. (%) or mean ± standard deviation
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Statistical analysis
Data handling (data entry, verification, and analysis) 
was computerised using SPSS (Windows version 
23.0; IBM Corp, Armonk [NY], United States). Only 
the patients with complete drug profiles a nd a ll 
variables recorded were included. Any incomplete 
drug profile o r m issing v ariables ( eg, B MI) w ere 
considered missing data and were not included 
in the analysis. Independent samples t tests were 
used to compare BMI values between people taking 
different b eta-blockers. B inary l ogistic r egression 
was used to verify the contributions of various drug 
classes and co-morbidities on a stratified binary BMI 
parameter (normal and underweight vs overweight 
and obesity). Chi squared tests were used to detect 
any significant d ifferences in  th e pr oportion of  
patients with high BMI across different t ypes o f 




Among the 1665 individuals participating in 
the summer community outreach programme, 
data pertaining to 1053 were included in the 
analysis after screening against the inclusion and 
exclusion criteria. The p articipants’ d emographics 
and characteristics are shown in Table 1. People 
taking beta-blockers were generally heavier (mean 
BMI 24.6±3.7 vs 23.6±3.6, P<0.001). From the 
perspective of BP measurement readings, around 
80% of the participants (804/1053) had elevated BP 
measurements during the outreach visit; of these, 
one third (286/804) had no history of hypertension 
and were not on any medications likely to be used 
for treating hypertension. The remaining two thirds 
(518/804) self-reported having hypertension. From 
the perspective of self-reported hypertension, 81.9% 
of those with self-reported hypertension (513/626) 
had hypertensive readings, and only 6% (40/626) 
had normotensive readings; the remaining ones had 
borderline hypertensive readings (12%, 73/626).
Overall, 185 (18%) of the 1053 participants 
were using one beta-blocker. Among the range of 
beta-blockers used, atenolol and metoprolol were 
the most frequently prescribed (40% and 53%, 
respectively), followed by propranolol (5%) and 
bisoprolol (2%). Among the beta-blocker users, the 
majority (95%, 176/185) had a self-reported history 
of hypertension. In those participants with self-
reported hypertension who were not using beta-
blockers (n=451), the main antihypertensive agents 
prescribed were calcium channel blockers (71.3%), 
angiotensin-converting enzyme inhibitors (22.3%), 
angiotensin receptor blockers (12.1%), alpha-
blockers (7.9%), methyldopa (4.2%), hydralazine 
(1.0%), and reserpine (0.2%).
Body mass index and beta-blocker use
Overall, 54.1% (570/1053) of the participants were 
overweight or obese. The summary of patients’ 
BMI with or without beta-blockers is summarised 
in Table 2. After adjusting for consumption of 
various weight-altering drug classes, binary logistic 
regression showed that beta-blockers were the only 
drug class that made a significant contribution to 
stratified BMI status (ie, classification as overweight 
or obese) [Table 3]. Among those prescribed beta-
blockers (n=185), a significantly higher proportion 
was either overweight or obese compared with those 
who were not taking beta-blockers (n=868) [64.8% 
vs 51.8%, P=0.002; Table 2]. This difference is most 
evident when comparing the proportion of patients 
with obesity across beta-blocker users and non-users 
(45.9% vs 32.1%, respectively; P=0.002).
 Participants deemed to have hypertension 
(based solely on self-reported diagnosis of 
hypertension plus verification against medication 
profile, but not on BP measurement during the 
outreach service) had a significantly higher BMI than 
those who were normotensive (mean BMIs: 24.3±3.6 
vs 22.9±3.5, respectively; P<0.001). Although 
this difference may not be clinically significant, 
it triggered further sub-analysis on participants 
with hypertension diagnosis. A sub-analysis on the 
patients with self-reported diagnosis of hypertension 
was performed to confirm the association between 
the use of beta-blockers and BMI (Table 4). Among 
these participants with self-reported diagnosis 
of hypertension (n=626), a significantly higher 
proportion of patients with obesity (BMI >25) was 
observed in those using atenolol compared with 
those taking metoprolol (58.9% vs. 38.5%, P=0.031) 
or those who did not use any beta-blockers (58.9% 
vs 38.4%, P=0.007). Those using atenolol had a 
significantly higher BMI than those who did not use 
beta-blockers (mean BMIs: 25.3±3.5 vs 24.1±3.6, 
P=0.01).
Binary logistic regression analysis found that 
loop diuretics were associated with BMI reduction. 
However, concerning mechanism and indication, 
loop diuretics function by enhancing salt and 
water excretion and are clinically used to maintain 
* Data are shown as No. (%)
TABLE 2.  Body mass index distribution of people who were 
and were not using beta-blockers*
Beta-blocker use
No (n=868) Yes (n=185)
Underweight 55 (6%) 6 (3%)
Normal 363 (42%) 59 (32%)
Overweight and obese 450 (52%) 120 (65%)
#  Beta-blocker use and obesity  # 
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euvolaemia or prevent volume expansion.26 In 
other words, it makes no significant contribution to 
alteration of dry body weight, which is used for BMI 
determination and obesity evaluation. Therefore, 
despite the above findings, loop diuretics were 
excluded from our further analysis.
Discussion
Our study presents preliminary findings regarding 
the potential real-world impact of beta-blockers on 
weight, noting the high proportion of community-
dwelling older adults using these agents. We found 
a significant association between obesity/overweight 
with the use of beta-blockers in older Chinese adults. 
The difference was largely driven by the strong 
association between obesity and atenolol (rather 
than other beta-blockers). This may have important 
ramifications on therapeutic choice if the association 
is causal.
The potential mechanisms by which beta-
blockers may induce weight gain include reduction 
of total energy expenditure (by 5%-10%), which may 
involve (1) decreased resting energy expenditure; 
(2) increased feelings of tiredness, with subsequent
reduction of non-exercise-associated thermogenesis;
(3) inhibition of lipolysis; and (4) enhancement of
insulin resistance.27
Many studies of Caucasian populations have 
reported the weight gain effects of beta-blockers, 
being associated with a mean weight gain of 1.2 kg 
(range, -0.4 kg to 3.5 kg),27 which could explain our 
findings of 2.6 kg higher mean body weight in people 
taking beta-blockers (mean body weight of people 
who did vs did not take beta-blockers: 57.8±9.7 kg 
vs 55.2±9.8 kg, respectively; P=0.002 respectively), 
but we do not have longitudinal data to make pre- 
versus post-drug commencement comparisons. 
Several studies have compared impact on weight 
between selected beta-blockers and alternative 
antihypertensive medications, ie, atenolol versus 
captopril,2 metoprolol versus thiazide diuretics,3 
atenolol versus chlorthalidone,4 and atenolol versus 
nifedipine,5 with all reporting weight gain (or 
reduced weight loss) in the beta-blocker treatment 
group. A long-term follow-up study also reported 
sustained weight gain in a propranolol treatment 
group compared with a placebo group.28
TABLE 3.  Binary logistic regression analysis on body mass index status*
B Standard error Wald df P value Exp(B) 95% CI for Exp(B)
Age -0.020 0.009 5.289 1 0.021 0.980 0.963-0.997
Beta-blockers 0.558 0.172 10.481 1 0.001 1.747 1.246-2.448
Insulin 1.130 0.670 2.842 1 0.092 3.095 0.832-11.510
Sulfonylurea 0.032 0.276 0.013 1 0.908 1.033 0.601-1.773
Loop diuretics 1.180 0.441 7.165 1 0.007 3.256 1.372-7.727
Antidepressants 0.288 0.528 0.297 1 0.585 1.334 0.474-3.758
Metformin -0.064 0.206 0.096 1 0.756 0.938 0.627-1.404
Constant 1.597 0.684 5.457 1 0.019 4.938
Abbreviations: 95% CI = 95% confidence interval; df = degrees of freedom; SE = standard error
* Body mass index status as a binary variable: normal and underweight vs overweight and obese. A few remaining drug groups
were not included in this regression analysis because of the low number of patients taking them (<10 out of 1053). For details, 
please refer to Table 1. Omnibus tests of model coefficients: for step, block, model, Chi squared=27.345, df=7, P<0.001. Predicted
value of the dependent variable based on the full logistic regression model is 55.3%
* Data are shown as No. (%) of participants, unless otherwise specified
TABLE 4.  Body mass index distribution among older Chinese adults taking different beta-blockers*
Total population (n=1053) P 
value


















55 (6%) 363 (42%) 171 (20%) 279 (32%) - 18 (4%) 164 (37%) 96 (21%) 173 (38%) - 37 (9%) 199 (48%) 75 (18%) 106 (25%)
Atenolol 1 (1%) 22 (30%) 8 (11%) 43 (58%) <0.001 1 (1%) 21 (29%) 8 (11%) 43 (59%) 0.009 0 1 (100%) 0 0
Metoprolol 4 (4%) 32 (33%) 25 (26%) 37 (38%) 0.183 2 (2%) 30 (33%) 24 (26%) 35 (39%) 0.617 2 (29%) 2 (29%) 1 (14%) 2 (29%)
Propranolol 1 (11%) 4 (45%) 1 (11%) 3 (33%) 0.880 0 4 (57%) 1 (14%) 2 (29%) 0.700 1 (50%) 0 0 1 (50%)
Bisoprolol 0 1 (25%) 1 (25%) 2 (50%) 0.808 0 1 (25%) 1 (25%) 2 (50%) 0.926 0 0 0 0
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 Despite the findings of previous studies, to 
date, there have been no intraclass head-to-head 
studies in humans regarding beta-blocker-induced 
weight gain. The two beta-blockers of note, atenolol 
and metoprolol, both being β1-selective beta-
blockers, seemingly have no plausible cause that 
could account for such differences between them. 
Our study suggests that atenolol and metoprolol 
(the two most commonly used beta-blockers in 
Hong Kong13,14) may have different effects on weight. 
We found a significantly higher BMI and a higher 
proportion of patients with obesity in those taking 
atenolol compared with those who did not, especially 
among those defined as being hypertensive. This 
difference in obesity was also significant for the 
comparison with metoprolol. Patients taking 
metoprolol did not show any significant difference 
from patients who were not on any beta-blockers.
 In our study, the mean difference in BMI 
between those using atenolol and no beta-blockers 
was about 1.2. Converting the mean BMI difference 
in a 60-kg woman reveals a mean body weight 
difference of 3.1 kg. Whether such a degree of weight 
gain is clinically significant in light of age-related 
weight gain is worthwhile to discuss. Indeed, age-
related weight gain is an important factor of concern. 
According to a study of older Chinese adults, the 
median weight change from 20 years old to baseline 
was 11.8 kg and 11.5 kg for men and women, 
respectively.29 Another 10-year follow-up study also 
reported that a modest weight gain (2.5-5 kg) was not 
associated with an increase in mortality.30 Therefore, 
a gain of 3.1 kg alone may not be clinically significant. 
Yet, such a modest weight gain can be additive to 
physiological age-related weight gain and contribute 
to obesity. While age-related weight gain may not be 
a modifiable factor, the selection of pharmacotherapy 
is definitely one. Particularly, the use of beta-blockers 
may not actually be the best therapeutic option for 
hypertension management. Switching to other first-
line agents that have no weight gain effects would 
reduce the possibilities to become obese.
 Given our findings, it is important to note the 
variable recommendations around the use of beta-
blockers in hypertension management. Although 
a number of international guidelines advocate the 
use of beta-blockers in patients with both obesity 
and hypertension,9-11 the 2017 American Heart 
Association guideline criticised atenolol for its 
inferior efficacy in treatment of hypertension.6 
Moreover, a meta-analysis of atenolol versus other 
antihypertensive treatments also reported higher 
overall and cardiovascular mortality and more 
frequent strokes with atenolol treatment.31 Given 
these reservations about atenolol and our findings of 
higher prevalence of obesity in those taking atenolol, 
it is uncertain whether atenolol should continue to be 
the most-used drug for hypertension. This is relevant 
to many parts of the world, including Hong Kong, 
where atenolol appears to be the first-line therapy for 
hypertension in older patients and may be associated 
with an adverse effect on weight and BMI.
 To the best of our knowledge, this is the first 
study to evaluate the association between BMI 
and beta-blocker use in a Chinese population. 
Additionally, this is the first study highlighting the 
intraclass differences between beta-blockers in 
terms of possible weight gain effects (as illustrated 
by the proportion of obesity), specifically in the 
hypertensive Chinese population. Therefore, 
our findings have implications for local clinical 
practice given the high rate of use of beta-blockers, 
particularly atenolol, in the older adults in Hong 
Kong, despite guideline recommendations.
 In considering this study’s findings, it is 
important to acknowledge some of its limitations. 
First, given the cross-sectional nature of the 
study, no temporal or causal relationships can be 
fully assessed or confirmed. We only found an 
association between beta-blocker usage and obesity 
in hypertensive patients. We did not assess weight 
gain, as the term weight gain has a temporal element 
that should be validated with duration of drug 
therapy and weight changes throughout a certain 
period. Second, there is an issue with ‘confounding 
by indication’: it is possible that some study patients 
were obese when their antihypertensive therapy was 
initiated and, consequently, their physicians elected 
to use beta-blockers, given the recommendation by 
the few international consensuses and guidelines.9-12 
However, since this was a post-hoc analysis based on 
a cross-sectional study, it is difficult to figure out the 
temporal sequence—whether beta-blockers were 
initiated because the patients were obese, or the 
patients became obese after taking beta-blockers. 
Third, the results were subject to selection bias 
because (a) study participation was voluntary, likely 
representing those who were more physically and/or 
socially active, and (b) those who were home-bound 
or had limited access to outdoor environments 
were not available for inclusion. Third, although 
the selection criteria were not designed in favour of 
women, the greater participation of women in our 
study is common in community-based investigations 
in Hong Kong,32-37 probably reflecting their greater 
participation in community-based and health-
related activities.32,33 Although the self-reported 
diagnoses of hypertension were verified against the 
medication profiles, it is possible that beta-blockers 
were prescribed for an alternative indication, such as 
ischaemic heart disease.
Conclusion
Our study has reported a high proportion of 
beta-blocker use among Hong Kong older adults 
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with hypertension. Beta-blocker users, and more 
specifically atenolol users, have a significantly 
higher BMI, as well as a higher propensity towards 
obesity compared with non-users. Our results 
can remind clinicians of the possibility that beta-
blockers, particularly atenolol, may worsen weight 
control in hypertensive patients with obesity or 
cause significant weight gain in those who are not 
yet obese. Our findings taken together with other 
guideline reservations cast doubt on whether beta-
blockers, particularly atenolol, should be the major 
drug prescribed to older adults with hypertension.
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